First Berlin Equity Research Initiates Coverage on Cantourage Group SE

First Berlin Equity Research GmbH has begun coverage on Cantourage Group SE, assigning a Buy rating with a price target of €11. The report, dated May 7, 2026, highlights the company's strong position in the European medical cannabis market. It leverages a capital-efficient platform to integrate sourcing, processing, and distribution across both regulated and telemedicine channels.

The analysis suggests Cantourage is more resilient to regulatory changes than previously anticipated by the market. Despite concerns over potential reforms in Germany impacting the equity narrative, Cantourage is believed to be well-prepared to adjust through its diverse product portfolio, pharmacy access, and growing geographic presence. As regulatory uncertainties diminish, the focus may shift towards its growth potential and improving profitability.